Generalized anxiety disorder (GAD) is a chronic psychiatric disorder with a lifetime prevalence of 5% and with dis-abling symptoms. The disorder, which shows high comorbidity with other medical and psychiatric diseases, poses personal and economic burden by deteriorating the quality of life. The aim of the long-term GAD treatment is to reduce psychic and somatic symptoms, to regulate the sleep, improve the functions of the patient, improve the quality of life, to treat the comorbid conditions, and finally to provide remission and prevent relapses. Recently, effective and safe treatment options that act through new mechanisms were brought into use due to the requirement for new agents that can effectively treat anxiety without causing problems associated with current treatment approaches, and due to advances in the fields of neuroanatomy and neurochemistry. In this study, pharmacotherapy for GAD was reviewed and pregabalin, which seems promising among the other drugs that have been newly introduced, was also mentioned.